Jeroen Bakker, PhD, joined Novo Holdings in 2018 as a Senior Associate in the Novo Seeds team. Previously, Jeroen worked at the corporate investment group of Merck KGaA, M Ventures, focusing on early-stage investments in US, EU and Israel. Prior to this, Jeroen was active as a consultant acquiring several millions in non-dilutive funding for biotech and translational academic research. Jeroen worked in biotech at Syntaxin Ltd (acquired by Ipsen) and published several articles on innate immunity in high-ranking journals such as Journal of Experimental Medicine while obtaining his PhD in immunology from the University of Amsterdam.
About Novo Seeds - Novo Seeds is the early stage investment arm of Novo Holdings. Novo Seeds identifies, builds and invests in innovative start-up companies founded on strong science with the aim of developing products with the potential to transform patient treatment. In addition to providing managerial and strategic support to start-ups, Novo Seeds has the financial capability to invest all the way to the exit. For more information, please visit: www.novoholdings.dk
Sascha Berger, PhD, joined the TVM Capital Life Science team in Munich in 2016. He is active in deal flow generation, investment due diligence, deal and exit transactions, investor communication as well as corporate finance aspects of the fund. Sascha has a strong academic and business background with more than ten years of professional transaction and strategy experience. He has a track-record of concluding 25+ deals, many of those he led as the responsible manager in his previous role as Senior M&A Manager in a private equity-backed global technology corporation. Prior to this role, Sascha successfully advised multiple renowned clients in pharma and technology sectors working as (senior) consultant for PwC and the Boston Consulting Group. Sascha holds a Master in technology management from Munich University of Technology with majors in (bio-) chemistry and entrepreneurial finance. Later he completed his Ph.D. studies in finance while already working for PwC.
About TVM Capital Life Science - TVM Capital Life Science is one of Europe’s oldest Venture Capital funds with teams based in Munich and Montreal. Our investment professionals draw upon the experience, international approach and demonstrated success of about 100 dedicated Life Science exits from our portfolio. These exits include 45 initial public offerings on the NASDAQ, and various European Exchanges and multiple trade sales and mergers. With more than two decades of experience in picking promising entrepreneurs, concepts and products for development, and building successful entrepreneurial companies, we are acutely aware of what it takes to build a world class technology, product or company, and astute at supporting management teams to bring companies and projects to value inflection points. Our most recent fund focuses on a new investment approach to developing early-stage pharmaceutical assets in a capital efficient fashion, to a human proof-of-concept in single asset companies. Besides this, we are actively seeking investments in innovative later-stage biotech, pharmaceutical, medtech and digital-health companies in Europe, North America and Asia. For more information, please visit www.tvm-lifescience.com.
Asiya Giniatullina, PhD is Senior Associate in the Forbion Naarden office. Between 2013 and 2018, Asiya has worked at bluebird bio in Cambridge MA in Business Development, Alliance Management and Research Strategy roles. At bluebird, Asiya has contributed to expanding the company pipeline by helping identify and evaluate early-stage technologies and new disease indications. She has been involved in executing and managing several collaborative projects in gene therapy. Most recently, she has led the planning and execution of a program for a new gene therapy product candidate, from ideation through proof-of-concept study, and mapping out the development plan. Before moving to the US and joining bluebird bio, Asiya worked as analyst intern at Forbion. Asiya holds a Ph.D. in Neuroscience from the VU University Amsterdam, M.S. in Medical Biotechnology and B.S. in Biotechnology from the University of Trieste, Italy.
About Forbion - Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands and Germany. We work closely together with entrepreneurs to support their technologies and products designed to transform people’s lives. For this purpose, we are backing innovative ideas not only with venture capital but also with our broad network as well as in-house expertise in drug development and company building. Forbion manages well over EUR 1 billion across ten funds, currently invests out of its € 360 million FCF IV fund and is actively looking for innovative opportunities in the arena of pharmaceuticals, medical devices and diagnostics. For more information, please visit www.forbion.com.
Lena Krzyzak, PhD, joined HTGF in 2016 as Investment Manager in the Life Science Team and is currently responsible for six portfolio companies in the fields of medical technology, drug development, biotechnology and digital health as well as for sourcing and completion of new early-stage investments. Before, she worked as Postdoctoral Researcher at the University Hospital in Erlangen and obtained her PhD in Immunology within a DFG-funded Fast-track PhD program at the Friedrich-Alexander University Erlangen-Nürnberg. The thesis resulted in several publications in reowned journals. Lena received her Bachelor’s degree from the Georg-August University Göttingen with studies abroad in Umeå (Sweden) and Singapore.
About HTGF - HTGF (Bonn/Berlin) is a seed investor that finances high-potential, tech-driven start-ups. With EUR 892 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge over 500 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and start-up experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in a range of sectors, including software, media, internet, hardware, automation, health care, chemicals and life sciences. Investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Energy, the KfW Banking Group and Fraunhofer-Gesellschaft e.V., as well as a number of well-known companies spanning all industries and segments. For more information, please visit: www.high-tech-gruenderfonds.de
Joachim (JR) Rothe, PhD, joined LSP in 2002 and is a Managing Partner of the firm. Prior to joining LSP, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm, where he rose to head up their European investment franchise. Previously, he worked at McKinsey & Company in Germany and at Roche in Switzerland. He serves or has served on the boards of 4- Antibody (CH, now NASDAQ: AGEN), Affectis (D), Atlas Genetics (UK), Atugen (D, now LSE:SLN Silence Therapeutics), Bioxell (I, now SIX: Cosmo Pharmaceuticals), Cardior (D), Cellerix (E, now NYSE Euronext: Tigenix), IDEA (D), Morphochem (D, now: Biovertis), Idenix (USA, then NASDAQ: IDIX, now Merck), Luxendo (D, now Bruker Corp), Nouscom (CH), Okairos (CH, now: GSK), Omrix Biopharmaceuticals (NYSE: OMRI, then J&J), Scion Pharmaceuticals (USA), t.Breeders (NASDAQ: Viacell, then NYSE:PKI) and U3 Pharma (D, now: Daiichi-Sankyo). In addition, he serves pro bono on the boards of various tech transfer organizations such as Ascenion, AWS. Joachim obtained a Master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. His thesis was supervised by Georges Köhler, a Nobel laureate in Medicine. Joachim has authored numerous articles in leading scientific publications, including Nature.
About LSP - LSP (Life Sciences Partners) is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s, the LSP team has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With over €1.7 billion ($2.0 billion) of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is Europe’s leading life sciences investor. For more information, please visit: www.lspvc.com